| Name | Title | Contact Details |
|---|
Actym Therapeutics has engineered a new drug modality harnessing the power of a genetically modified bacterial vehicle that safely introduces therapeutic payloads to activate the immune response in the tumor microenvironment. To achieve targeted anti-tumor effects, we have developed a systemically administered treatment that exploits intrinsic TME-specific metabolites, enabling selective enrichment of the bacterial vehicle in tumors. After cell-specific entry, our lead candidate, ACTM-838, positively activates tumor-resident myeloid cells and delivers two synergistic payloads, optimized IL-15 and STING, unlocking a comprehensive and durable innate and adaptive anti-tumor immune response. With the ability to tailor our platform utilizing a range of payload combinations, we aim to achieve a new level of therapeutic impact for cancer patients across multiple tumor types.
Eccrine Systems, Inc., is focused on the development of non-invasive disposable electronic patches that accurately measure and transmit real-time data about human sweat. Applications for our technology and IP span market opportunities within medicine, industry, and sports. We seek to establish exclusive collaborations with downstream partners who understand the opportunity for embedding and deploying our technology in their market-specific applications. Our role in these collaborations is the modular development and prototyping of desired sweat sensor features and capabilities. Our partners embed our technology in their commercial applications and translate data about sweat and other biometrics into high value products for their customers.
Genizon BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. Our lead asset is inhaled pirfenidone (AP01) for the treatment of IPF. With offices in Seattle and San Diego, Avalyn`s experienced clinical and inhaled product development team is rapidly advancing AP01 for the treatment of IPF and additional pipeline candidates for IPF and other severe respiratory diseases.
CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases.